Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China
Clinical Kidney Journal · 02.11.2026 · 19 (11)
DOI: 10.1093/ckj/sfag354 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Kidney Journal, online erschienen am 09.10.2026. Verfasst von Fengyu Wen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Health Data Science at Peking University, Beijing, China. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project of China, National High Level Hospital Clinical Research Funding.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Fengyu Wen, Jinwei Wang, Chao Yang, Fulin Wang, Yan Li, Luxia Zhang; Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabet
Autor:innen und Institutionen
- National Institute of Health Data Science at Peking University, Beijing, China.
- School of Data Science and Artificial Intelligence, Beijing University of Chinese Medicine, Beijing, China.
- Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
- Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
- Center for Digital Health and Artificial Intelligence, Peking University First Hospital, Beijing, China.
ORCID-Profile: Jinwei Wang, Yan Li
Förderung
- National Natural Science Foundation of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project of China
- National High Level Hospital Clinical Research Funding
- State Key Laboratory of Vascular Homeostasis and Remodeling
- Peking University
- Young Elite Scientists Sponsorship Program by CAST
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Wen, F., Wang, J., Yang, C., Wang, F., Li, Y., & Zhang, L. (2026). Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China. Clinical Kidney Journal, 19(11). https://doi.org/10.1093/ckj/sfag354
Vancouver
Wen F, Wang J, Yang C, Wang F, Li Y, Zhang L. Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China. Clinical Kidney Journal. 2026;19(11). doi:10.1093/ckj/sfag354
BibTeX
@article{Wen2026,
author = {Wen, Fengyu and Wang, Jinwei and Yang, Chao and Wang, Fulin and Li, Yan and Zhang, Luxia},
title = {Cost-effectiveness of dapagliflozin for chronic kidney disease with and without diabetes in China},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {11},
doi = {10.1093/ckj/sfag354}
}
EUVIMED